VASO
Vaso Corporation0.1700
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
29.91MP/E (TTM)
8.50Basic EPS (TTM)
0.02Dividend Yield
0%Recent Filings
8-K
Bylaws amended for flexibility
Vaso Corporation amended its Bylaws on February 11, 2026, boosting board flexibility on stockholder meeting timing and virtual formats while eliminating stockholder actions without meetings. Changes conform director numbers to the Articles, add a Chief Operating Officer role, and strengthen indemnification standards. Governance tightened. Full details in Exhibit 3.1.
8-K
Shareholders elect directors, approve pay
Vaso Corporation shareholders elected Behnam Movaseghi, Jane Moen, and Leon Dembo as Class II directors for three-year terms at the December 17, 2025 annual meeting, with 120M of 176M shares voting. The advisory Say on Pay proposal passed strongly. Shareholders recommended triennial Say on Pay votes—56% backed three years. Board adopted it; next in 2028.
8-K
Vaso sells IT unit to Nanox
Vaso Corporation agreed to sell its VasoHealthcare IT subsidiary to Nano-X Imaging on November 19, 2025, for up to $800,000—$200,000 at closing, $600,000 earnout—slated to close in weeks. This unit, under 5% of revenue, gets divested to sharpen focus on core operations. Sale proceeds fund other lines. Earnout hinges on performance.
10-Q
Q3 FY2025 results
Vaso swung to $1.5M operating income in Q3 ended September 30, 2025, up from $1.4M loss y/y (derived), on 9% revenue growth to $22.7M fueled by 19% jump in professional sales commissions while IT edged 1% higher; gross margin lifted to 61% from 57%. YTD revenue rose 4% to $62.1M yet operating loss narrowed to $0.1M from $1.9M, with EPS at $0.00 matching diluted shares of 175.9M. Cash swelled to $34.9M on $9.0M operating cash flow, less $0.6M capex for $8.4M FCF (derived); $3M revolver undrawn, in covenant compliance. Terminated Achari merger in September 2024. GEHC deal runs through 2026.
10-Q
Q2 FY2025 results
Vaso's Q2 revenue dipped 1% y/y to $19.957M while holding steady q/q, with IT up slightly but professional sales off 4% on lower GEHC imaging deliveries; YTD revenue grew 1% y/y to $39.418M. Gross margins slipped to 59% from 60% y/y amid IT mix shift to lower-margin network services, fueling a swing to $0.4M operating loss from $1.0M profit—SG&A climbed 11% on sales headcount. Cash swelled to $32.6M after $6.2M operating cash flow beat last year's $1.7M, with $867K capex yielding $5.4M FCF (derived); $3M revolver undrawn despite covenant waiver. Deferred commissions hit $38.1M, signaling backlog strength. GEHC ties expose delivery risks.
IPO
Website
Employees
Sector
Industry
CCLD
CareCloud, Inc.
3.21+0.02
GEHC
GE HealthCare Technologies Inc.
82.25-2.20
HAE
Haemonetics Corporation
81.11+0.71
HTFL
Heartflow, Inc.
26.47+0.84
INFU
InfuSystems Holdings, Inc.
9.29+0.05
MASI
Masimo Corporation
134.52-2.88
TDOC
Teladoc Health, Inc.
7.41+0.07
UIS
Unisys Corporation New
2.84-0.04
VEEV
Veeva Systems Inc.
219.30-0.80
WORX
SCWorx Corp.
0.21-0.01